Science.bio Is Closing Again — What It Means for Nasal Spray Peptide Researchers

Science.bio built its reputation as one of the most accessible and well-organized research peptide suppliers in the United States, with a particular strength that set them apart from most competitors: a dedicated focus on nasal spray peptide delivery. While the majority of the research peptide market centered on lyophilized powder and injectable reconstituted solutions, Science.bio invested in formulated nasal spray products that removed the reconstitution step entirely — a significant barrier for many researchers and self-experimenting practitioners.

Their nasal spray catalog included some of the most sought-after cognitive and nootropic peptides — Semax and Selank chief among them — alongside compounds like PT-141, Epithalon, and BPC-157 in nasal delivery format. For researchers interested in needle-free administration or in peptides where intranasal delivery offers pharmacokinetic advantages, Science.bio was often the first and sometimes only name on the list.

Their product documentation, including batch-specific Certificates of Analysis, gave them a level of credibility that was unusual in the nasal spray niche, where quality control is even harder to verify than in the broader peptide market.

What makes this closure particularly notable is that it is not the first time Science.bio has shut down. The company previously ceased operations under earlier FDA enforcement pressure and market pressures, only to relaunch — rebranded and restructured — after a period of dormancy. That previous return gave many in the research community confidence that the brand had staying power. The second closure puts that perception to rest.

The pattern is consistent with what has happened across the broader US research peptide industry since 2023: even well-established, quality-focused companies operating in good faith find themselves unable to sustain operations as payment processor restrictions tighten, banking relationships become untenable, and FDA enforcement letters create unacceptable legal exposure.

Science.bio is not a company that failed due to quality issues or customer trust problems — their reputation in the community was generally strong. Their second closure is a market failure, not a product failure.

Intranasal peptide delivery is not simply a convenience preference — for certain compounds and research applications, it offers meaningful pharmacokinetic and practical advantages over subcutaneous injection.

The nasal mucosa provides a highly vascularized surface with relatively high permeability to small peptide molecules. For peptides like Semax and Selank — both developed in Russia specifically for intranasal administration — this is the delivery route for which their pharmacology was designed. Intranasal delivery of these compounds allows for rapid absorption, avoids first-pass hepatic metabolism, and for some compounds, may facilitate delivery across the blood-brain barrier via olfactory pathways.

Additionally, the nasal spray format is simply more practical for many users: no syringes, no reconstitution, no refrigeration sensitivity in the same way, and no needle-associated concerns. For researchers running longer protocols or studying populations who are averse to injection, nasal delivery opens research avenues that powder or injectable formats cannot.

The closure of Science.bio creates a real gap for this delivery category specifically. Not every peptide supplier offers nasal spray formulations, and fewer still do so with the quality documentation necessary to trust the product.

Peptides Commonly Available as Nasal Sprays

The following compounds were among the most researched in nasal spray format — many of which were staples of the Science.bio catalog.

Finding a comparable replacement for Science.bio is harder than finding a general peptide supplier. The nasal spray format requires formulation expertise beyond simply sourcing raw peptide — the spray solution must be appropriately buffered, preserved, and stabilized, and the concentration must be verified independently. A replacement needs to clear a higher bar than the average powder-only supplier.

For researchers looking for a direct replacement for Science.bio's nasal spray catalog, NasalSprayPeptides.com is our top recommendation. They are one of the very few suppliers who specialize in this delivery format specifically — rather than treating it as an afterthought to a powder catalog.

As always, verify that any nasal spray supplier provides batch-specific documentation for their finished spray products — not just the underlying raw peptide. The quality gap in this niche is real, and the formulation process introduces additional variables that powder sourcing does not.